Your browser doesn't support javascript.
loading
Co-enrichment of CD8-positive T cells and macrophages is associated with clinical benefit of tislelizumab in solid tumors.
Ye, Dingwei; Desai, Jayesh; Shi, Jingwen; Liu, Si-Yang Maggie; Shen, Wei; Liu, Tengfei; Shi, Yang; Wang, Dan; Liang, Liang; Yang, Silu; Ma, Xiaopeng; Jin, Wei; Zhang, Pei; Huang, Ruiqi; Shen, Zhirong; Zhang, Yun; Wu, Yi-Long.
Afiliación
  • Ye D; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
  • Desai J; Department of Medical Oncology, Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, Australia.
  • Shi J; Clinical Biomarkers, BeiGene (Beijing) Co., Ltd., 6 Jianguomenwai Avenue, Central International Trade Center, 18th Floor, Tower D Chaoyang District, Beijing, 100022, China.
  • Liu SM; Department of Hematology, First Affiliated Hospital, The Clinical Medicine Postdoctoral Research Station, Jinan University, Guangzhou, China.
  • Shen W; Clinical Biomarkers, BeiGene (Beijing) Co., Ltd., 6 Jianguomenwai Avenue, Central International Trade Center, 18th Floor, Tower D Chaoyang District, Beijing, 100022, China.
  • Liu T; Clinical Biomarkers, BeiGene (Beijing) Co., Ltd., 6 Jianguomenwai Avenue, Central International Trade Center, 18th Floor, Tower D Chaoyang District, Beijing, 100022, China.
  • Shi Y; Clinical Biomarkers, BeiGene (Beijing) Co., Ltd., 6 Jianguomenwai Avenue, Central International Trade Center, 18th Floor, Tower D Chaoyang District, Beijing, 100022, China.
  • Wang D; Clinical Biomarkers, BeiGene (Beijing) Co., Ltd., 6 Jianguomenwai Avenue, Central International Trade Center, 18th Floor, Tower D Chaoyang District, Beijing, 100022, China.
  • Liang L; Clinical Biomarkers, BeiGene (Beijing) Co., Ltd., 6 Jianguomenwai Avenue, Central International Trade Center, 18th Floor, Tower D Chaoyang District, Beijing, 100022, China.
  • Yang S; Clinical Biomarkers, BeiGene (Beijing) Co., Ltd., 6 Jianguomenwai Avenue, Central International Trade Center, 18th Floor, Tower D Chaoyang District, Beijing, 100022, China.
  • Ma X; Clinical Biomarkers, BeiGene (Beijing) Co., Ltd., 6 Jianguomenwai Avenue, Central International Trade Center, 18th Floor, Tower D Chaoyang District, Beijing, 100022, China.
  • Jin W; Clinical Biomarkers, BeiGene (Beijing) Co., Ltd., 6 Jianguomenwai Avenue, Central International Trade Center, 18th Floor, Tower D Chaoyang District, Beijing, 100022, China.
  • Zhang P; Clinical Biomarkers, BeiGene (Beijing) Co., Ltd., 6 Jianguomenwai Avenue, Central International Trade Center, 18th Floor, Tower D Chaoyang District, Beijing, 100022, China.
  • Huang R; Department of Statistics, BeiGene (Shanghai) Co., Ltd., Shanghai, China.
  • Shen Z; Clinical Biomarkers, BeiGene (Beijing) Co., Ltd., 6 Jianguomenwai Avenue, Central International Trade Center, 18th Floor, Tower D Chaoyang District, Beijing, 100022, China.
  • Zhang Y; Clinical Biomarkers, BeiGene (Beijing) Co., Ltd., 6 Jianguomenwai Avenue, Central International Trade Center, 18th Floor, Tower D Chaoyang District, Beijing, 100022, China. yun.zhang@beigene.com.
  • Wu YL; Department of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 51008, China. syylwu@live.cn.
Biomark Res ; 11(1): 25, 2023 Mar 07.
Article en En | MEDLINE | ID: mdl-36879284
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Biomark Res Año: 2023 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Biomark Res Año: 2023 Tipo del documento: Article País de afiliación: China